Sara M Tolaney

Oncology experts discuss research on metastatic triple-negative breast cancer, including a predictive survival tool and treatment approaches like immunotherapy and antibody drug conjugates. They address challenges in diagnosing and managing complications, exploring immune-related adverse events and CNS progression. The synergy of immune checkpoint inhibitors and ADCs, optimizing treatment sequencing, patient experiences with TDXD therapy, and the role of PARP inhibitors are also highlighted.